Received by email:
File: 04 28 2015 InvestorUpdated2015_Final.docx
Abattis Bioceuticals Investor update for Q2 2015
Vancouver, BC - April 28, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT) (OTCQX: ATTBF), a
--->botanical drug development company that develops and licenses natural health products, medicines, extractions and ingr
--->edients for the pharmaceutical, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabino
--->id compounds, today announces a press release to update its current shareholders.
Our primary strategy is to align with or acquire like-minded companies that support our botanical drug development eff
--->orts in the most efficient manner. Abattis has two focuses: Product sales through the research, development and sale o
--->f nutraceutical products; and the development of botanical drugs. The extraction, refining and sciences divisions of A
--->battis all form the botanical drug development divisions. The BioExtracts division is being re-aligned to fit into the
---> extraction and refining category to couple it with our already existing labs and intellectual property.
Abattis would like to update Investors on work underway at the Company and the status of work under the Company's whol
--->ly-owned subsidiaries and partners. The Company is currently;
Evaluating current assets;
Awaiting Northern Vine's rebranded websites to go live;
Expecting Biocell to bring products to the direct sales market;
Working through the research and development (R&D) at Biocube following a successful growth trial run;
Holding a future pipeline of product opportunities in IJuana; and
Assessing the use of the Phytalab business model for deployment into Northern Vine.
Since 1997, the Company has actively purchased assets and intellectual property. Currently the assets are at various s
--->tages of development. Abattis' management is actively reviewing all of the Company's assets and opportunities while as
--->sessing their alignment with the Company's positioning in the nutraceuticals industry, with core assets being evaluate
--->d on their ability to provide revenue generation in the near term. Assets that do not fit into Management's core focus
---> are being reviewed for disposal. Disposing of the non-core assets will lead to additional value by better positioning
---> the Company. Abattis is working to position itself as a leader in the botanical medicine field, with a focus on pain
--->management.
Abattis' wholly-owned and partner companies are completing business plan reviews, which have led the company toward a
--->rebranding effort commencing with updated websites. The Experion Biotechnologies Inc. (Experion) and Northern Vine Ca
--->nada Inc. ("Northern Vine") websites will be going live in the near term (www.northernvine.ca). Abattis' main website
--->and it's additional subsidiaries websites will be revised as the company's assets are repositioned.
Abattis, through our wholly-owned subsidiary Biocell Labs Inc. ("Biocell"), intends on bringing several products to ma
--->rket. Currently, Biocell has 10 new natural product formulas that are near market, as they await pending patents and N
--->PN numbers. These products will include cannabinoid compounds in US jurisdictions where permitted. Biocell will not be
---> marketing any of these products direct to retail. Biocell has established relations to facilitate its strategy to de
--->velop proprietary product formulations for rebranding and marketing by others. By developing branding and marketing pa
--->rtners, Biocell will save time and money while not losing focus on other objectives. The capital saved will allow Bioc
--->ell to generate future products based on existing intellectual property. Capital and attention spent on research and d
--->evelopment ("R&D") will result in the development of future products. Biocell is currently preparing additional detail
--->ed information on each of the 10 products, which will be disseminated, as it is available.
Biocell is also readying its patent pending Nitric Oxide product in a unique delivery system to bring it to the market
--->place. Nitric Oxide has been proven in studies, conducted by parties unrelated to the Company, to promote blood flow
--->and is a signaling molecule for cardiovascular health.
Biocube Green Grow Systems ("Biocube") is the Company's proprietary grow chamber using MgO board, an anti-microbial pr
--->oduct. Over the last 6 months Biocube has gone through several successful trials of the proprietary grow chamber with
---> both Ocimum tenuiflorum (i.e., "Holy Basil") and Arabidopsis. Both trials were successful and allowed Biocube to furt
--->her refine design specifications. Biocube is currently performing R&D testing for yield and analysis purposes, as a fo
--->llow up to the two products mentioned above. Biocube plans to relocate the proprietary grow chamber to a i-502 locatio
--->n in Washington state in the near future and is preparing to sell grow systems that are ready for market. Biocube's go
--->al in relation to this product remains to develop a superior sustainable growth chamber for use in the medical marijua
--->na industry as well as produce markets.
iJuana Cannabis Inc. ("iJuana") serves two purposes within Abattis. iJuana currently holds extra production capacity
--->for future production at a site in Squamish BC, which is properly zoned. Federal licensing applications are still pend
--->ing, and as a result iJuana is currently holding Biocube's inventory of proprietary grow chambers in place. iJuana is
---> also the holder of an additional 78 licensed natural health products (under the name Animo Wellness Corporation on He
--->alth Canada's website). The natural product numbers (NPNs) found on Health Canada's website are active and embody futu
--->re products for iJuana.
Phytalab is a licensed I 502-testing lab in Washington State. Currently, Abattis management is in the process of reco
--->gnizing Phytalab's core values and profit generating potential. Phytalab is able to test for heavy metals, foreign mat
--->erial screening, moisture content and microbial burden, making it an integral part in testing marijuana suppliers. Phy
--->talab is not simply a medical marijuana testing facility; rather, it has an expansive profile of services including th
--->e testing of a wide variety of botanicals, research and development activities, genetic identification, and publicatio
--->n of standards through Abattis affiliated laboratories. Northern Vine intends to become a similarly positioned lab in
--->Canada that tests products and raw materials to Health Canada's standards. Abattis will expand our Labs into differen
--->t countries and states, once our brands are established.
There are other potential divisional developments that will be discussed in the future. Management felt that this upd
--->ate could serve to clarify some of the existing investor questions. Management is also looking into holding an annual
---> investor conference call at a later date that can be dial in.
The Company wishes to announce that pursuant a consulting agreement with arm's length parties, it has issued an aggreg
--->ate of 72,414 common shares at a deemed price of CAD 0.145/share as consideration for services provided to the Company
--->.
ON BEHALF OF THE BOARD
"Bill Fleming" Bill Fleming, CEO
For further information, contact the Company at (604) 336-0881 or at news@abattis.com.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY
--->FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION This press release contains forward-looking statements. The use of any of the words "antic
--->ipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are in
--->tended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on
--->which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-look
--->ing statements because the Company can give no assurance that they will prove to be correct. Since forward-looking sta
--->tements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Thes
--->e statements speak only as of the date of this press release. Actual results could differ materially from those curren
--->tly anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Disc
--->ussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertak
--->e to update this information at any particular time.
File: 04 28 2015 InvestorUpdated2015_Final.pdf
Suite
1040
�
855
West
Georgia
Street
Vancouver,
BC,
V6C
3H1
Tel:
(604)
336-0881
Abattis
Bioceuticals
Investor
update
for
Q2
2015
Vancouver,
BC
�
April
28,
2015
-
Abattis
Bioceuticals
Corp.
(the
"Company"
or
"Abattis")
(CSE:
ATT)
(OTCQX:
ATTBF),
a
botanical
drug
development
company
that
develops
and
licenses
natural
health
products,
medicines,
extractions
and
ingredients
for
the
pharmaceutical,
nutraceutical,
bioceutical
and
cosmetic
markets
�
some
of
which
will
contain
cannabinoid
compounds,
today
announces
a
press
release
to
update
its
current
shareholders.
Our
primary
strategy
is
to
align
with
or
acquire
like-minded
companies
that
support
our
botanical
drug
development
efforts
in
the
most
efficient
manner.
Abattis
has
two
focuses:
Product
sales
through
the
research,
development
and
sale
of
nutraceutical
products;
and
the
development
of
botanical
drugs.
The
extraction,
refining
and
sciences
divisions
of
Abattis
all
form
the
botanical
drug
development
divisions.
The
BioExtracts
division
is
being
re-aligned
to
fit
into
the
extraction
and
refining
category
to
couple
it
with
our
already
existing
labs
and
intellectual
property.
Abattis
would
like
to
update
Investors
on
work
underway
at
the
Company
and
the
status
of
work
under
the
Company's
wholly-owned
subsidiaries
and
partners.
The
Company
is
currently;
- Evaluating
current
assets;
- Awaiting
Northern
Vine's
rebranded
websites
to
go
live;
- Expecting
Biocell
to
bring
products
to
the
direct
sales
market;
- Working
through
the
research
and
development
(R&D)
at
Biocube
following
a
successful
growth
trial
run;
- Holding
a
future
pipeline
of
product
opportunities
in
IJuana;
and
- Assessing
the
use
of
the
Phytalab
business
model
for
deployment
into
Northern
Vine.
Since
1997,
the
Company
has
actively
purchased
assets
and
intellectual
property.
Currently
the
assets
are
at
various
stages
of
development.
Abattis'
management
is
actively
reviewing
all
of
the
Company's
assets
and
opportunities
while
assessing
their
alignment
with
the
Company's
positioning
in
the
nutraceuticals
industry,
with
core
assets
being
evaluated
on
their
ability
to
provide
revenue
generation
in
the
near
term.
Assets
that
do
not
fit
into
Management's
core
focus
are
being
reviewed
for
disposal.
Disposing
of
the
non-core
assets
will
lead
to
additional
value
by
better
positioning
the
Company.
Abattis
is
working
to
position
itself
as
a
leader
in
the
botanical
medicine
field,
with
a
focus
on
pain
management.
Abattis'
wholly-owned
and
partner
companies
are
completing
business
plan
reviews,
which
have
led
the
company
toward
a
rebranding
effort
commencing
with
updated
websites.
The
Experion
Biotechnologies
Inc.
(Experion)
and
Northern
Vine
Canada
Inc.
("Northern
Vine")
websites
will
be
going
live
in
the
near
term
(www.northernvine.ca).
Abattis'
main
website
and
it's
additional
subsidiaries
websites
will
be
revised
as
the
company's
assets
are
repositioned.
Abattis,
through
our
wholly-owned
subsidiary
Biocell
Labs
Inc.
("Biocell"),
intends
on
bringing
several
products
to
market.
Currently,
Biocell
has
10
new
natural
product
formulas
that
are
near
market,
as
they
await
pending
patents
and
NPN
numbers.
These
products
will
include
cannabinoid
compounds
in
US
jurisdictions
where
permitted.
Biocell
will
not
be
marketing
any
of
these
products
direct
to
retail.
Biocell
has
established
relations
to
facilitate
its
strategy
to
develop
proprietary
product
formulations
for
rebranding
and
marketing
by
others.
By
developing
branding
and
marketing
partners,
Biocell
will
save
time
and
money
while
not
losing
focus
on
other
objectives.
The
capital
saved
will
allow
Biocell
to
generate
future
products
based
on
existing
intellectual
property.
Capital
and
attention
spent
on
research
and
development
("R&D")
will
result
in
the
development
of
future
products.
Biocell
is
currently
preparing
additional
detailed
information
on
each
of
the
10
products,
which
will
be
disseminated,
as
it
is
available.
Suite
1040
�
855
West
Georgia
Street
Vancouver,
BC,
V6C
3H1
Tel:
(604)
336-0881
Biocell
is
also
readying
its
patent
pending
Nitric
Oxide
product
in
a
unique
delivery
system
to
bring
it
to
the
marketplace.
Nitric
Oxide
has
been
proven
in
studies,
conducted
by
parties
unrelated
to
the
Company,
to
promote
blood
flow
and
is
a
signaling
molecule
for
cardiovascular
health.
Biocube
Green
Grow
Systems
("Biocube")
is
the
Company's
proprietary
grow
chamber
using
MgO
board,
an
anti-microbial
product.
Over
the
last
6
months
Biocube
has
gone
through
several
successful
trials
of
the
proprietary
grow
chamber
with
both
Ocimum
tenuiflorum
(i.e.,
"Holy
Basil")
and
Arabidopsis.
Both
trials
were
successful
and
allowed
Biocube
to
further
refine
design
specifications.
Biocube
is
currently
performing
R&D
testing
for
yield
and
analysis
purposes,
as
a
follow
up
to
the
two
products
mentioned
above.
Biocube
plans
to
relocate
the
proprietary
grow
chamber
to
a
i-502
location
in
Washington
state
in
the
near
future
and
is
preparing
to
sell
grow
systems
that
are
ready
for
market.
Biocube's
goal
in
relation
to
this
product
remains
to
develop
a
superior
sustainable
growth
chamber
for
use
in
the
medical
marijuana
industry
as
well
as
produce
markets.
iJuana
Cannabis
Inc.
("iJuana")
serves
two
purposes
within
Abattis.
iJuana
currently
holds
extra
production
capacity
for
future
production
at
a
site
in
Squamish
BC,
which
is
properly
zoned.
Federal
licensing
applications
are
still
pending,
and
as
a
result
iJuana
is
currently
holding
Biocube's
inventory
of
proprietary
grow
chambers
in
place.
iJuana
is
also
the
holder
of
an
additional
78
licensed
natural
health
products
(under
the
name
Animo
Wellness
Corporation
on
Health
Canada's
website).
The
natural
product
numbers
(NPNs)
found
on
Health
Canada's
website
are
active
and
embody
future
products
for
iJuana.
Phytalab
is
a
licensed
I
502-testing
lab
in
Washington
State.
Currently,
Abattis
management
is
in
the
process
of
recognizing
Phytalab's
core
values
and
profit
generating
potential.
Phytalab
is
able
to
test
for
heavy
metals,
foreign
material
screening,
moisture
content
and
microbial
burden,
making
it
an
integral
part
in
testing
marijuana
suppliers.
Phytalab
is
not
simply
a
medical
marijuana
testing
facility;
rather,
it
has
an
expansive
profile
of
services
including
the
testing
of
a
wide
variety
of
botanicals,
research
and
development
activities,
genetic
identification,
and
publication
of
standards
through
Abattis
affiliated
laboratories.
Northern
Vine
intends
to
become
a
similarly
positioned
lab
in
Canada
that
tests
products
and
raw
materials
to
Health
Canada's
standards.
Abattis
will
expand
our
Labs
into
different
countries
and
states,
once
our
brands
are
established.
There
are
other
potential
divisional
developments
that
will
be
discussed
in
the
future.
Management
felt
that
this
update
could
serve
to
clarify
some
of
the
existing
investor
questions.
Management
is
also
looking
into
holding
an
annual
investor
conference
call
at
a
later
date
that
can
be
dial
in.
The
Company
wishes
to
announce
that
pursuant
a
consulting
agreement
with
arm's
length
parties,
it
has
issued
an
aggregate
of
72,414
common
shares
at
a
deemed
price
of
CAD
0.145/share
as
consideration
for
services
provided
to
the
Company.
ON
BEHALF
OF
THE
BOARD
"Bill
Fleming"
Bill
Fleming,
CEO
For
further
information,
contact
the
Company
at
(604)
336-0881
or
at
news@abattis.com.
NEITHER
THE
CANADIAN
SECURITIES
EXCHANGE
NOR
ITS
REGULATIONS
SERVICES
PROVIDER
HAVE
REVIEWED
OR
ACCEPT
RESPONSIBILITY
FOR
THE
ADEQUACY
OR
ACCURACY
OF
THIS
RELEASE.
Suite
1040
�
855
West
Georgia
Street
Vancouver,
BC,
V6C
3H1
Tel:
(604)
336-0881
FORWARD
LOOKING
INFORMATION
This
press
release
contains
forward-looking
statements.
The
use
of
any
of
the
words
"anticipate",
"continue",
"estimate",
"expect",
"may",
"will",
"project",
"should",
"believe"
and
similar
expressions
are
intended
to
identify
forward-looking
statements.
Although
the
Company
believes
that
the
expectations
and
assumptions
on
which
the
forward-looking
statements
are
based
are
reasonable,
undue
reliance
should
not
be
placed
on
the
forward-looking
statements
because
the
Company
can
give
no
assurance
that
they
will
prove
to
be
correct.
Since
forward-looking
statements
address
future
events
and
conditions,
by
their
very
nature
they
involve
inherent
risks
and
uncertainties.
These
statements
speak
only
as
of
the
date
of
this
press
release.
Actual
results
could
differ
materially
from
those
currently
anticipated
due
to
a
number
of
factors
and
risks
various
risk
factors
discussed
in
the
Company's
Management's
Discussion
and
Analysis
under
the
Company's
profile
on
www.sedar.com.
While
the
Company
may
elect
to,
it
does
not
undertake
to
update
this
information
at
any
particular
time.
© 2024 Canjex Publishing Ltd. All rights reserved.